Pfizer Launches Cost Savings Programme on TrumpRx
Pfizer has rolled out a new cost-savings initiative, TrumpRx, aimed at making medicines more affordable for US patients. The programme covers over 30 brands across major therapy areas and reinforces the company’s commitment to lowering drug prices under its landmark agreement with the Trump administration.
Albert Bourla | 07/02/2026 | By News Bureau | 136
Pfizer Completes Acquisition of Metsera
Pfizer has finalised its acquisition of Metsera, adding a portfolio of differentiated, clinical-stage obesity therapies with the potential to redefine future treatment standards. The deal strengthens and reshapes Pfizer’s internal medicine portfolio, positioning the company to compete more aggressively in therapeutic areas, globally.
Albert Bourla | 14/11/2025 | By Dineshwori | 160
Pfizer signs Agreement with US Government to Lower Drug Costs for American Patients
Pfizer has voluntarily agreed to implement measures designed to ensure Americans receive comparable drug prices to those available in other developed countries and pricing newly launched medicines at parity with other key developed markets.
Albert Bourla | 01/10/2025 | By Dineshwori | 184
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy